Want to hire this expert for a project? Request a quote for free.
Profile Details
Subject Matter Expertise
Services
Work Experience
Research Associate
Pacific Northwest National Lab
August 2015 - June 2017
Education
PhD (Department of Pharmaceutical Sciences)
Texas Technical University Health Sciences Center School of Pharmacy
August 2010 - December 2014 
Certifications
- Certification details not provided.
Publications
BOOK
Wang, W., Nag, S., Zhang, R.(2016). Pharmacokinetics and pharmacodynamics in breast cancer animal models . Methods in Molecular Biology. 1406. p. 271-287.
JOURNAL ARTICLE
Nag, S., Qin, J.-J., Patil, S., Deokar, H., Buolamwini, J.K., Wang, W., Zhang, R., Nag, S., Qin, J.-J., Patil, S., et al.(2016). A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study . Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 969. p. 235-240.
Nag, S., Qin, J.-J., Voruganti, S., Wang, M.-H., Sharma, H., Patil, S., Buolamwini, J.K., Wang, W., Zhang, R.(2015). Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice . Biomedical Chromatography. 29. (5). p. 654-663.
Wang, W., Nag, S.A., Zhang, R.(2015). Targeting the NFκB signaling pathways for breast cancer prevention and therapy . Current Medicinal Chemistry. 22. (2). p. 264-289.
Voruganti, S., Qin, J.-J., Sarkar, S., Nag, S., Walbi, I.A., Wang, S., Zhao, Y., Wang, W., Zhang, R.(2015). Oral nano-delivery of anticancer ginsenoside 25-OCH<inf>3</inf>-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action . Oncotarget. 6. (25). p. 21379-21394.
Wang, W., Qin, J.-J., Voruganti, S., Nag, S., Zhou, J., Zhang, R.(2015). Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications . Medicinal Research Reviews. 35. (6). p. 1220-1267.
Yu, J.-X., Voruganti, S., Li, D.-D., Qin, J.-J., Nag, S., Xu, S., Velu, S.E., Wang, W., Zhang, R.(2015). Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats . Chinese Journal of Natural Medicines. 13. (7). p. 0554-0560.
Qin, J.-J., Nag, S., Wang, W., Zhou, J., Zhang, W.-D., Wang, H., Zhang, R.(2014). NFAT as cancer target: Mission possible? . Biochimica et Biophysica Acta - Reviews on Cancer. 1846. (2). p. 297-311.
Wang, W., Cheng, J., Qin, J.-J., Voruganti, S., Nag, S., Fan, J., Gao, Q., Zhang, R.(2014). RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo . Oncotarget. 5. (22). p. 11567-11582.
Wang, W., Nag, S., Zhang, X., Wang, M.-H., Wang, H., Zhou, J., Zhang, R.(2014). Ribosomal Proteins and Human Diseases: Pathogenesis, Molecular Mechanisms, and Therapeutic Implications . Medicinal Research Reviews.
Nag, S., Zhang, X., Srivenugopal, K.S., Wang, M.-H., Wang, W., Zhang, R.(2014). Targeting MDM2-p53 interaction for cancer therapy: Are we there yet? . Current Medicinal Chemistry. 21. (5). p. 553-574.
Wang, W., Qin, J.-J., Voruganti, S., Srivenugopal, K.S., Nag, S., Patil, S., Sharma, H., Wang, M.-H., Wang, H., Buolamwini, J.K., et al.(2014). The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models . Nature Communications. 5.
Yu, J., Nag, S.A., Zhang, R.(2013). Advances in translational pharmacological investigations in identifying and validating molecular targets of natural product anticancer agents . Current Cancer Drug Targets. 13. (5). p. 596-609.
Qian, B., Nag, S.A., Su, Y., Voruganti, S., Qin, J.-J., Zhang, R., Cho, W.C.S.(2013). miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents . Current Cancer Drug Targets. 13. (5). p. 519-541.
Nag, S., Qin, J., Srivenugopal, K.S., Wang, M., Zhang, R.(2013). The MDM2-p53 pathway revisited . Journal of Biomedical Research. 27. (4). p. 254-271.
Qin, J.-J., Jin, H.-Z., Huang, Y., Zhang, S.-D., Shan, L., Voruganti, S., Nag, S., Wang, W., Zhang, W.-D., Zhang, R.(2013). Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from Inula lineariifolia Turcz . European Journal of Medicinal Chemistry. 68. p. 473-481.
Wang, W., Zhang, X., Qin, J.-J., Voruganti, S., Nag, S.A., Wang, M.-H., Wang, H., Zhang, R.(2012). Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2 . PLoS ONE. 7. (7).
Nag, S., Nadkarni, D.H., Qin, J.-J., Voruganti, S., Nguyen, T., Xu, S., Wang, W., Wang, H., Velu, S.E., Zhang, R.(2012). Anticancer activity and molecular mechanisms of action of makaluvamines and analogues . Molecular and Cellular Pharmacology. 4. (2). p. 69-81.
Nag, S.A., Qin, J.-J., Wang, W., Wang, M.-H., Wang, H., Zhang, R., Nag, S.A., Qin, J.-J., Wang, W., Wang, M.-H., et al.(2012). Ginsenosides as anticancer agents: In vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action . Frontiers in Pharmacology. 3 FEB.
Wang, W., Ao, L., Rayburn, E.R., Xu, H., Zhang, X., Zhang, X., Nag, S.A., Wu, X., Wang, M.-H., Wang, H., et al.(2012). KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology . PLoS ONE. 7. (9).
Qin, J.-J., Nag, S., Voruganti, S., Wang, W., Zhang, R.(2012). Natural product MDM2 inhibitors: Anticancer activity and mechanisms of action . Current Medicinal Chemistry. 19. (33). p. 5705-5725.
Ratings and Comments
Total Projects Awarded:
Comments:
